Safety of Extended Propofol Infusions in Critically Ill Pediatric Patients

Area of Science:

• Pediatric Critical Care Medicine
• Pharmacology
• Anesthesiology

Background:

• Propofol, a widely used sedative and anesthetic, has raised concerns regarding propofol-related infusion syndrome (PRIS) in critically ill pediatric patients.
• Existing safety data for propofol infusions in this population are limited, particularly for doses and durations exceeding established guidelines.

Purpose of the Study:

• To evaluate the risk of propofol infusions in the pediatric intensive care unit (PICU) when administered at doses and durations beyond previously described safety parameters.
• To identify potential covariables associated with propofol infusion risks in critically ill children.

Main Methods:

• Retrospective cohort analysis of 173 pediatric patients who received propofol in the PICU.
• Patients were stratified into two groups: those receiving infusions >48 hours and those receiving <48 hours.
• Demographic data and daily clinical variables were collected for up to seven days post-infusion initiation or until cessation.

Main Results:

• No cases of propofol-related infusion syndrome (PRIS) were observed in either group, despite high mean propofol doses (>67 mcg/kg/min).
• Patients receiving infusions >48 hours exhibited higher illness severity scores and a greater need for vasoactive infusion support compared to the <48-hour cohort.
• No significant differences were noted in lactate levels or other biochemical parameters between the two groups.

Conclusions:

• This pilot study suggests the feasibility of propofol infusion in critically ill pediatric patients, even at extended durations and high doses, without observed PRIS.
• The findings highlight the need for larger, multicenter studies to solidify clinical recommendations for propofol use in pediatric intensive care settings.